Dynorphin, a class of opioid neuropeptides involved in pain, addiction, and mood regulation, has been reported to undergo metabolic dysfunction following exogenous exposure in animal models, potentially contributing to the onset of neurodegenerative diseases [78]. Here, PDYN is linked to neurodegenerative disease.